Sirolimus is an immunosuppressive drug inhibiting mammalian target of rapamycin and consequently T-lymphocyte proliferation. 1 It is widely used in solid organ transplantation (SOT), particularly in renal and liver transplantation. 2 It can also be used to prevent or treat GVHD after allogeneic stem cell transplantation (allo-SCT). 3 The mucocutaneous side effects of sirolimus have been well described in renal [4] [5] [6] and liver [7] [8] [9] transplant recipients but are under-reported in the allo-SCT setting. [10] [11] [12] The most consistently reported mucocutaneous side effects in the SOT setting include acne-like eruptions, edemas, oral ulcerations and onychopathies. [4] [5] [6] [7] [8] [9] We report here a case of a sirolimus-related anal ulceration without any other mucocutaneous lesion in a female patient after allo-SCT.
A 59-year-old woman with a medical history of Sjogren's syndrome underwent in June 2014 an unrelated allo-SCT for a diffuse large B-cell lymphoma in second CR after a reduced intensity conditioning regimen with fludarabine (30 mg/m 2 /day from day − 5 to day − 1), IV busulfan (0.8 mg/kg × 4/day at days − 4 and − 3) and rabbit antithymocyte globulin (Thymoglobulin, 2.5 mg/kg at days − 2 and − 1). She had no medical history of other autoimmune disease, inflammatory bowel disease or digestive ulcers. Because of a renal insufficiency, cyclosporine A (CsA) was discontinued at 6 weeks and replaced by sirolimus at 2 mg/day after a loading dose of 6 mg. At that time, she was also receiving penicillin, trimethoprim-sulfamethoxazole, acyclovir, fluconazole, gabapentin and clonazepam (for a painful peripheral neuropathy secondary to previous chemotherapies). Four weeks after the introduction of sirolimus, she complained of a anal pain of increasing intensity. The clinical examination revealed a 1-cm anal ulceration with a fibrinoid base ( Figure 1 ). She had no fever and clinical examination was otherwise normal, including skin and oral mucosa. Blood cell counts and renal and liver function tests were normal. She had mild diarrhoea, with 2-4 loose stools per day (o 500 ml/day), without abdominal pain, ileus or bloody stools. She had no nausea or vomiting. A rectosigmoidoscopy was performed to exclude the diagnosis of gut acute GVHD. Macroscopic and histopathological examinations of the rectal mucous membrane were normal. No colonoscopy or gastroscopy was performed. Then we looked for an infection. The syphilis and HIV tests were negative. The detections by PCR of HSV, CMV, human herpesvirus 6, EBV, VZV and adenovirus were negative in blood and ulceration. The detections by PCR of enterovirus and human papillomavirus were negative in the ulceration. The parasitological examination of feces was negative and no yeast or mold was isolated from the ulceration. The detections by PCR of Chlamydiae trachomatis, Neisseria gonorrhoeae and Mycoplasma genitalium were negative in the ulceration. No methicillin-resistant Staphylococcus aureus was isolated from the ulceration. A multi-drug resistant Pseudomonas aeruginosa was detected in the ulceration and the stools. In the absence of fever, we considered it as a contamination from the feces and not as the cause of the ulceration. As a consequence, no antibiotic active against P. aeruginosa was administered. In the absence of a convincing infectious cause, the hypothesis of a sirolimus-related ulceration was considered. The blood level of sirolimus was 13.7 ng/ml (normal, 6-10 ng/ml). Sirolimus was discontinued and replaced by mycophenolate mofetil. Then the pain progressively improved and disappeared after 7 days. The mild diarrhoea also quickly disappeared. The following days, the situation improved leading to a complete healing in 1 month without any other therapeutic intervention or drug withdrawal (Figure 2) .
To our knowledge, this is the first report of a sirolimus-related anal ulceration after allo-SCT. Several arguments support the responsibility of sirolimus in the present case. First, the diagnosis 4 weeks after the introduction is in line with previous reports in SOT setting, indicating that mucocutaneous toxicities occur in the first weeks. 4, 9 Then complete healing was obtained after discontinuation of sirolimus without any other therapeutic intervention or drug withdrawal. Additionally, no virus, parasite or fungus was isolated from the ulceration. The role of P. aeruginosa was very unlikely as healing was achieved without any active antibiotic. We acknowledge that the absence of re-challenge with sirolimus is a limitation in our case. We considered it unethical because of the risk of relapse and the possible use of mycophenolate mofetil. We also acknowledge that a complication of the Sjogren's syndrome might have favoured the development of the ulceration even if common signs of the syndrome were absent.
The mucocutaneous toxicity of sirolimus has been well described in the SOT setting with acne-like eruptions, edemas, oral ulcerations and onychopathies but no isolated anal ulceration has been reported so far. [4] [5] [6] [7] [8] [9] Three studies have reported on the toxicity of sirolimus after allo-SCT. [10] [11] [12] Renal insufficiency, hemolytic uremic syndrome, increases in cholesterol and triglyceride serum levels and hematological toxicity were common Figure 1 . Anal ulceration at diagnosis. but no mocucutaneous adverse event was reported. [10] [11] [12] These previous data underline the originality of the present case. Of note, we cannot exclude the presence of lesions in the colon or upper gastro-intestinal tract as no colonoscopy or gastroscopy was performed in our patient.
The question as to whether the ulceration could have healed after dose reduction instead of withdrawal remains open. The blood level in our patient was indeed slightly above the normal range. However, in two previous studies after renal transplantation, there was no significant correlation between the blood level and the development of any type of mucocutaneous disorder. 5, 6 Because of these data and because anal ulceration significantly increases the risk of bacterial infections in such immunosuppressed patients, we chose to discontinue sirolimus instead of reducing the dose to obtain the healing as quickly as possible.
Finally, in cases of anal ulceration after allo-SCT, an infectious cause should always be considered, as well as GVHD, autoimmune or other inflammatory conditions, but physicians should also be aware of the risk of sirolimus-related ulceration for an appropriate management in these heavily immunosuppressed patients. This is important since a recent study demonstrating similar long-term outcomes, more rapid engraftment, and less oropharyngeal mucositis of the combination tacrolimus/sirolimus compared with tacrolimus/methotrexate as GVHD prophylaxis might lead to an increased use of sirolimus. 13 Figure 2. Healed anal ulceration 1 month after discontinuation of sirolimus.
